Original Article
Protection against a Malaria Challenge by Sporozoite Inoculation
N Engl J Med 2009; 361:468-477July 30, 2009
- Abstract
Background
An effective vaccine for malaria is urgently needed. Naturally acquired immunity to malaria develops slowly, and induction of protection in humans can be achieved artificially by the inoculation of radiation-attenuated sporozoites by means of more than 1000 infective mosquito bites.
Methods
We exposed 15 healthy volunteers — with 10 assigned to a vaccine group and 5 assigned to a control group — to bites of mosquitoes once a month for 3 months while they were receiving a prophylactic regimen of chloroquine. The vaccine group was exposed to mosquitoes that were infected with Plasmodium falciparum, and the control group was exposed to mosquitoes that were not infected with the malaria parasite. One month after the discontinuation of chloroquine, protection was assessed by homologous challenge with five mosquitoes infected with P. falciparum. We assessed humoral and cellular responses before vaccination and before the challenge to investigate correlates of protection.
Results
All 10 subjects in the vaccine group were protected against a malaria challenge with the infected mosquitoes. In contrast, patent parasitemia (i.e., parasites found in the blood on microscopical examination) developed in all five control subjects. Adverse events were mainly reported by vaccinees after the first immunization and by control subjects after the challenge; no serious adverse events occurred. In this model, we identified the induction of parasite-specific pluripotent effector memory T cells producing interferon-γ, tumor necrosis factor α, and interleukin-2 as a promising immunologic marker of protection.
Conclusions
Protection against a homologous malaria challenge can be induced by the inoculation of intact sporozoites. (ClinicalTrials.gov number, NCT00442377.)
Media in This Article
Figure 1
Study Design and Enrollment.Figure 2
Parasitemia in the Vaccine Group and the Control Group.Article Activity
- Article
Malaria is responsible for a significant burden of morbidity and mortality in the developing world, and an effective vaccine against this disease is urgently needed.1 Despite decades of research, a licensed vaccine is still not available, largely because immunity to Plasmodium falciparum malaria is considered difficult to acquire, whether through natural exposure or artificially through vaccination. A further critical factor is our incomplete understanding of precisely what constitutes protective antimalarial immunity in humans.
The possibility of vaccinating humans against P. falciparum malaria was raised originally by the success of the radiation-attenuated sporozoite model developed several decades ago.2,3 Irradiation of infectious mosquitoes disrupts the gene expression of sporozoites, which remain capable of hepatocyte invasion but are no longer capable of complete liver-stage maturation or progression to the pathogenic blood stage.4 Infection of human volunteers with irradiated sporozoites thus exposes them to liver-stage antigens and generates pre-erythrocytic immunity. However, the requirement of a minimum of 1000 bites by irradiated mosquitoes during five or more immunization sessions in order to successfully induce sterile immunity in humans5 precludes this method for routine immunization.
A subunit vaccine can be developed on the basis of antigens expressed by pre-erythrocytic, intraerythrocytic, or sexual stages of the parasite. Unfortunately, results of many such subunit vaccines in humans have been disappointing. To date, only one candidate vaccine, which is based on the circumsporozoite protein and known as RTS,S, has progressed to phase 3 field trials. The protection induced by this vaccine is encouraging, but the ultimate success of this approach remains to be determined.6-9
In rodent models, sterile protection against malaria can be achieved by the inoculation of intact sporozoites while treating the animals concomitantly with chloroquine,10 a drug that kills parasites in the asexual blood stage but not in the pre-erythrocytic stage.11 The efficacy of this treatment is significantly higher than that of the radiation-attenuated sporozoite model.12 We therefore designed a proof-of-concept study in volunteers who had not been previously exposed to malaria to investigate whether protection can be induced by this approach in humans and to explore the immune responses elicited.
Methods
Study Subjects
We recruited 15 healthy volunteers between the ages of 18 and 45 years who had no history of malaria or of living in an area in which malaria is endemic in the 6 months before study entry. Only one volunteer had ever been in an endemic area, several years earlier. All volunteers underwent routine physical examination and hematologic and biochemical screening at the Clinical Research Center at Radboud University Nijmegen Medical Centre. The results of serologic analysis for the human immunodeficiency virus (HIV), hepatitis B and C, and asexual P. falciparum parasites were negative in all subjects.
Study Oversight
All subjects provided written informed consent. The trial was approved by the institutional review board at the Radboud University Nijmegen Medical Centre. The study sponsor, the Dioraphte Foundation, was not involved in the design of the study, in the gathering or analysis of the data, or in the writing of the manuscript. All authors vouch for the accuracy and completeness of the data.
Study Design
We randomly assigned the subjects in a double-blind fashion to two study groups: 10 to a vaccine group and 5 to a control group (Figure 1Figure 1
Study Design and Enrollment.). The mean (±SD) age of the subjects was 22.0±1.5 years in the vaccine group and 24.0±1.4 years in the control group; seven subjects in the vaccine group were women, as were four subjects in the control group.Chloroquine was provided to all subjects in a standard prophylactic regimen of a loading dose of 300 mg on each of the first 2 days and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks. While receiving chloroquine, subjects in the vaccine group were exposed on three occasions at monthly intervals to bites of 12 to 15 mosquitoes that had been infected with P. falciparum, for a total exposure of bites from 36 to 45 infected mosquitoes per subject. Control subjects received bites from an equal number of uninfected mosquitoes on the same occasions.
Anopheles stephensi mosquitoes were reared according to standard procedures at our insectary. Infected mosquitoes were obtained by feeding on gametocytes of NF54, a chloroquine-sensitive strain of P. falciparum, as described previously.13 NF54 is genetically homogeneous but has not been formally cloned. Only the technicians who prepared the mosquitoes were aware of their infectivity status, and these staff members had no clinical involvement with the subjects or the investigators. Blood-engorged mosquitoes were dissected to confirm the presence of sporozoites. If necessary, feeding sessions were repeated until precisely the predefined number of infected mosquitoes had fed. However, a single feeding session was sufficient in 49 of 60 instances of immunization or challenge, whereas a second session was required in just 10 instances and a third session in only 1 instance.
On days 6 to 10 after each immunization by mosquito exposure, all subjects were followed on an outpatient basis, and blood was drawn for standard whole-blood counts and daily peripheral-blood smears. Any signs and symptoms were recorded by the attending physician as follows: mild events (easily tolerated), moderate events (interferes with normal activity), or severe events (prevents normal activity).
Eight weeks after the last immunization dose and 4 weeks after the discontinuation of chloroquine prophylaxis, all 15 subjects were challenged by exposure to the bites of five mosquitoes that were infected with the homologous NF54 strain of P. falciparum. This period was considered to be sufficient for chloroquine levels to drop below those that might be inhibitory to parasite multiplication.14 All subjects were checked twice daily on an outpatient basis from day 5 to day 21 for symptoms and signs of malaria, and hematologic tests and peripheral-blood smears were performed.
If results of peripheral-blood testing were positive, subjects were treated with a standard curative combination regimen of 80 mg of artemether and 480 mg of lumefantrine, followed by five identical doses at 8, 24, 36, 48, and 60 hours. The subjects were then followed closely for 3 days. Complete cure was confirmed on the basis of peripheral-blood smears. All subjects who continued to have negative results on the peripheral-blood smear from the day of infection until day 21 after the challenge were presumptively treated with artemether–lumefantrine.
Hematologic and biochemical measures were determined in routine fashion at the hospital's central clinical laboratory. The use of nucleic acid sequence–based amplification and real-time polymerase-chain-reaction (PCR) assays to determine the densities of P. falciparum parasites have been described previously.15,16 Chloroquine levels were measured by liquid chromatography.17,18 Minimum therapeutic concentrations for plasma chloroquine levels maintained by the laboratory were 30 μg per liter.14
Immunologic Analysis
Venous whole blood was collected in Vacutainer cell-preparation tubes (CPT, Becton Dickinson) before the first immunization and again before the malaria challenge. Plasma was collected and stored at −70°C. Peripheral-blood mononuclear cells were isolated by density gradient centrifugation, frozen in fetal-calf serum containing 10% dimethylsulfoxide, and stored in liquid nitrogen. Antibody titers were assessed by enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assay, according to standard protocols.19-21 Cellular responses to cryopreserved asexual parasites were assessed by 24-hour in vitro peripheral-blood–stimulation assays,22 followed by intracellular cytokine staining with the use of a Fix and Perm Kit (Caltag Laboratories) and flow cytometry. A more detailed description of these immunologic assays is provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.
Statistical Analysis
We performed flow cytometric analysis using CellQuest software, and all analyses were performed with the use of SPSS software. Differences in responses among subjects at various time points and between subjects in the vaccine group and those in the control group were analyzed by nonparametric measures (Wilcoxon and Mann–Whitney tests, respectively). A two-sided P value of less than 0.05 was considered to indicate statistical significance.
Results
Study Subjects
All 15 subjects completed the immunization phase of the study. All subjects received chloroquine prophylaxis and subsequently underwent a malaria challenge (Figure 1).
No parasites were seen in the peripheral-blood smears of any of the 10 subjects in the vaccine group after each of the three immunization sessions during chloroquine prophylaxis. However, after the first immunization, a brief submicroscopic parasitemic episode was detected in all vaccinees (Figure 2AFigure 2
Parasitemia in the Vaccine Group and the Control Group.). This finding was not unexpected, since chloroquine has no effect against either sporozoites, liver-stage parasites, or the early ring forms of the first generation of blood-stage parasites that are caused by merozoites released from mature hepatic schizonts.11 After each of the subsequent two immunizations, a progressively reduced incidence and burden of submicroscopic parasitemia was seen.In line with these findings, all vaccinees reported solicited or unsolicited symptoms that were recorded as adverse events at least once during the immunization phase. With the exclusion of local itching after the mosquito bites, adverse events were most commonly reported after the first immunization (in 9 of 10 subjects), with headache being the most frequent symptom (reported by 7 subjects) (Table 1Table 1
Adverse Events after the First, Second, and Third Exposures to Immunizing Mosquito Bites and after Challenge with Infectious Mosquito Bites.). Only a few adverse events were reported in the vaccine group subsequently (in two subjects after the third immunization). Severe adverse events were reported by three vaccinees: two had a fever above 39°C after the first immunization, and one reported severe malaise after the last immunization.After challenge with the homologous NF54 strain of P. falciparum, asexual blood-stage parasites were detected in peripheral-blood smears of all five control subjects between days 7 and 11 after exposure (mean prepatent period, 9.2 days). Real-time PCR analyses revealed the expected cyclical multiplication of blood-stage parasites (Figure 2B). The clinical course and kinetics of parasite multiplication were similar to those in previous studies involving subjects who had not been exposed to malaria,23,24 with all control subjects reporting severe events, in particular fever above 39°C and malaise (Table 1). In contrast, there was no evidence of blood-stage parasites in any of the vaccinees at any time during the post-challenge follow-up period until day 21, either by repeated microscopy of peripheral-blood smears or by real-time PCR analyses (Figure 2B). Interestingly, in the week after the malaria challenge, nine vaccinees reported mild-to-moderate events. No serious adverse events occurred during any part of the trial, and all 15 subjects completed follow-up according to protocol.
Mean peak plasma levels of chloroquine and desethylchloroquine were 76 μg per liter (range, 58 to 104) and 13 μg per liter (range, 5 to 33), respectively, 24 hours after administration; levels did not differ significantly between vaccinees and control subjects. The day before the malaria challenge, mean plasma levels of chloroquine and desethylchloroquine had dropped to 8 μg per liter (range, <5 to 14) and less than 5 μg per liter, respectively, which were deemed to be below the minimum therapeutic concentrations in vivo.14 Furthermore, blood-stage parasite multiplication kinetics in the control subjects were identical to those in previous studies,24 which suggested that any residual chloroquine levels had no measurable parasiticidal effect.
After immunization, antibody responses to both sporozoites and blood-stage parasites developed in vaccinees but not in control subjects, as shown by ELISA (Table 2Table 2
Antibody Reactivity.) and immunofluorescence assay (Figure 1 in the Supplementary Appendix). Seroconversion to the circumsporozoite protein, an immunodominant sporozoite-stage and liver-stage antigen, occurred in eight vaccinees. In contrast, seroconversion to crude asexual-stage antigen occurred in only three vacinees. Antibodies to two predominantly asexual antigens, apical membrane antigen 1 (AMA-1) and glutamate-rich protein (GLURP), both of which are leading vaccine candidates, were undetectable. These data are consistent with the relatively low-dose exposure to asexual blood-stage antigens in the vaccinees.Cellular immune responses were assessed by counting cytokine-producing cells in peripheral-blood specimens from the subjects, with the use of intracellular cytokine staining and flow cytometry after 24 hours of in vitro stimulation with erythrocytes infected with the homologous strain of P. falciparum or with uninfected erythrocytes (Figure 3Figure 3
In Vitro Pluripotent Cytokine Responses to Plasmodium falciparum Parasites on Flow Cytometry., and Figure 2 and Figure 3 in the Supplementary Appendix). Whereas cellular responses to uninfected erythrocytes did not differ in any experiment from responses to culture medium alone, stimulation with infected erythrocytes elicited small percentages of lymphocytes producing interferon-γ or TNF-α, but not interleukin-2, in the two groups before immunization (see day I-1 in Figure 2 in the Supplementary Appendix).Although there was no significant difference in the overall proportion of cells producing individual cytokines (interferon-γ or TNF-α) in either group after immunization (day C-1), a significant increase was observed in the proportion of cells producing multiple cytokines in response to infected erythrocytes in vaccinees, as compared with baseline: P=0.03 for the within-group comparison for interferon-γ and interleukin-2; P=0.046 for TNF-α and interleukin-2; and P=0.03 for interferon-γ, TNF-α, and interleukin-2 (Figure 3A, 3B, and 3C). The importance of these pluripotent lymphocytes in acquired immune protection is suggested by their higher cytokine content and may reflect better effector function (Figure 3D, 3E, and 3F). The major contributors to this increase in pluripotent lymphocytes with a response to infected erythrocytes were CD3+CD45RO+ memory-like T cells (P=0.02 for the comparison with day I-1) (Figure 3G, and Figure 3 in the Supplementary Appendix). CD4+CD8− cells showed a particularly marked response (P=0.005 for the comparison with day I-1) (Figure 3H). Most noticeably, these new pluripotent lymphocytes were predominantly of the effector memory CD62L−CD45RO+ phenotype (P=0.005 for the comparison with day I-1), although there was also a small but significant increase in the numbers of responding central memory CD62L+CD45RO+ cells in vaccinees (P=0.02 for the comparison with day I-1) (Figure 3I).
Discussion
Our study shows that the inoculation of intact sporozoites induces more effective protection against a homologous challenge with P. falciparum malaria than does irradiation-attenuated sporozoite immunization. In the endemic situation, however, nonsterile semi-immunity is acquired only after years of repeated natural exposure. We believe that the improved efficiency of our approach was due to a critical balance of exposure to pre-erythrocytic and intraerythrocytic antigens. In contrast to irradiated sporozoites that arrest early during liver-stage development,4 intact sporozoites under chloroquine cover mature fully and develop into a first generation of blood-stage parasites,11 thus presenting to the host's immune system a broader array of pre-erythrocytic antigens, as well as erythrocytic-stage antigens (albeit at relatively low dose).
The contribution of intraerythrocytic antigens to the development of protective immunity is suggested by Pombo et al.,25 who reported that repeated intravenous injection of ultra-low densities of blood-stage parasites, followed by drug cure with atovaquone–proguanil, induced protection in human volunteers against a similarly low-dose blood-stage challenge. However, caution needs to be exercised when interpreting the latter results, since residual concentrations of antimalarial drugs may partially or even fully have accounted for the observed protection.26
In the field, in contrast, patent parasitemia typically develops before patients seek treatment. In such patients, acute blood-stage infection may suppress the induction of protective pre-erythrocytic immunity, as has been shown in rodent models.27 Indeed, parasitemic episodes or attacks of febrile malaria in Kenyan children are prospectively associated with a poorer induction and more rapid attrition of cellular ex vivo and memory responses to a pre-erythrocytic P. falciparum antigen.28 Thus, patent parasitemia and probably chronic subpatent parasitemia, which occur regularly in children in endemic areas, appear to induce inhibitory mechanisms that delay the generation of protective antiparasite immunity. Meta-analysis of studies of intermittent preventive therapy in infants has decreased the concern about a rebound effect of prophylaxis and in some cases even indicates sustained protection after discontinuation of prophylaxis,29 thus further indicating that the acquisition and maintenance of protective immunity do not depend on chronic blood-stage exposure.
Thus, the salient feature of our approach seems to be the exposure of the immune system to a greater array of pre-erythrocytic and intraerythrocytic antigens, while restricting the development of symptomatic and potentially immunosuppressive parasitemia.30 Since NF54 is known to be a chloroquine-sensitive strain in vitro,31 we cannot formally exclude a synergistic effect of residual subtherapeutic chloroquine levels on immunologic parasite clearance. However, chloroquine levels before the malaria challenge approached or fell below the limit of detection and had no measureable parasiticidal effect in control subjects. Of more importance, the longevity of immunologic responses, both naturally acquired and vaccine-induced, remains a critical issue in malaria, and follow-up studies are planned to address this issue.
In this model, we have identified responses of pluripotent effector memory T cells as being associated with protection. In one study,32 undefined subgroups of lymphocytes with the same cytokine profile were associated with the induction and maintenance of antigen-specific T-cell memory in subjects who were immunized with pre-erythrocytic candidate malaria vaccines, but associations with protection were not explored. However, the potent effector function of pluripotent cells, as suggested by their high cytokine content, has been noted in other investigations that showed their protective role in other infectious diseases.33,34 Further detailed investigations will be necessary to determine the longevity of this immunologic response, its association with central memory-type T-cell activity, and its ability to serve as a true correlate of protection.
Since the magnitude of the first wave of parasitemia is thought to directly reflect the burden of erupting mature liver schizonts, the stepwise decrease of such organisms after each subsequent immunizing infection and the absence of PCR-detectable parasitemia after the malaria challenge would suggest that the protection in our model was primarily due to pre-erythrocytic immunity. However, a component of blood-stage immunity (i.e., the inhibition of erythrocyte invasion and maturation of minute liver-derived merozoite inocula that cannot be detected on PCR) is also possible. Indeed, we found that cellular responses to asexual blood-stage parasites before challenge were a discriminative marker of exposure and protection in our subjects, and similar immune responses may have contributed to protection in the rodent model.12 However, many of the best-studied P. falciparum antigens conferring protective immunity are shared among sporozoite, liver-stage, and blood-stage parasites.35,36 Thus, it is plausible that our findings represent the response to a broad antigenic repertoire that transcends parasitic developmental stages,37 making a division between pre-erythrocytic immunity and intraerythrocytic immunity inappropriate. At present, the stage specificity of the protective immune response must remain formally unresolved, although one way to further address this issue in future studies would be a blood-stage challenge.
Although the methods described here do not represent a widely implementable vaccine strategy, the induction of sterile protection against a homologous malaria challenge suggests that the concept of a whole-parasite malaria vaccine warrants further consideration. In addition, this model allows the nature of protective immune responses against malaria, both stage-specific and antigen-specific, to be further investigated.
Supported by the Dioraphte Foundation, by a fellowship from the European Union FP6 Network of Excellence (to Dr. McCall), and by grants from the NutsOhra Foundation (to Dr. van der Ven) and Agence Nationale de la Recherche in France (to Dr. Snounou).
Dr. Snounou reports receiving consulting fees from Sigma Tau and GlaxoSmithKline.
No other potential conflict of interest relevant to this article was reported.
Drs. Roestenberg and McCall contributed equally to this article.
We thank the study volunteers for their participation; K. Nganou Makamdop for help with the RT-PCR assays; J. Bakkers and W. Melchers for parasite genotyping; W. Arts, N. Huibers, and P. Beckers for reading blood slides; P. Houze and D. Mazier for chloroquine measurements; J. Klaassen, L. Pelser-Posthumus, J. Kuhnen, and A. Pouwelsen for technical assistance generating infected mosquitoes; the safety monitors for the study, B. Schouwenberg and P. Smits; and independent physician A. Brouwer.
Source Information
From the Departments of Medical Microbiology (M.R., M.M., J.H., J.W., A.J.F.L., G.J.G., M.V.-B., B.S., K.T., T.A., L.S., W.R., C.C.H., R.S.) and General Internal Medicine (Q.M., A.V.), Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; the Department of Parasitology, INSERM Unité 511, Hôpital Pitié–Salpêtrière, and the Université Pierre et Marie Curie — both in Paris (G.S.); and the Laboratory of Malaria Immunobiology, Singapore Immunology Network, Agency for Technology and Research, Biopolis, Singapore (L.R.).
Address reprint requests to Dr. Sauerwein at the Department of Medical Microbiology 268, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands, or at r.sauerwein@mmb.umcn.nl.
- References
References
1
Greenwood BM ,Fidock DA ,Kyle DE , et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008;118:1266-1276
CrossRef | Web of Science | Medline2
Clyde DF ,Most H ,McCarthy VC ,Vanderberg JP . Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973;266:169-177
CrossRef | Web of Science | Medline3
Nussenzweig RS ,Vanderberg J ,Most H ,Orton C . Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 1967;216:160-162
CrossRef | Web of Science | Medline4
Mellouk S ,Lunel F ,Sedegah M ,Beaudoin RL ,Druilhe P . Protection against malaria induced by irradiated sporozoites. Lancet 1990;335:721-721
CrossRef | Web of Science | Medline5
Hoffman SL ,Goh LM ,Luke TC , et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002;185:1155-1164
CrossRef | Web of Science | Medline6
Alonso PL ,Sacarlal J ,Aponte JJ , et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005;366:2012-2018
CrossRef | Web of Science | Medline7
Abdulla S ,Oberholzer R ,Juma O , et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008;359:2533-2544
Full Text | Web of Science | Medline8
Bejon P ,Lusingu J ,Olotu A , et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008;359:2521-2532
Full Text | Web of Science | Medline9
Aponte JJ ,Aide P ,Renom M , et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007;370:1543-1551
CrossRef | Web of Science | Medline10
Beaudoin RL ,Strome CP ,Mitchell F ,Tubergen TA . Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 1977;42:1-5
CrossRef | Web of Science | Medline11
Yayon A ,Vande Waa JA ,Yayon M ,Geary TG ,Jensen JB . Stage-dependent effects of chloroquine on Plasmodium falciparum in vitro. J Protozool 1983;30:642-647
Medline12
Belnoue E ,Costa FT ,Frankenberg T , et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004;172:2487-2495
Web of Science | Medline13
Ponnudurai T ,Lensen AH ,van Gemert GJ ,Bensink MP ,Bolmer M ,Meuwissen JH . Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 1989;98:165-173
CrossRef | Web of Science | Medline14
Rombo L ,Bergqvist Y ,Hellgren U . Chloroquine and desethylchloroquine concentrations during regular long-term malaria prophylaxis. Bull World Health Organ 1987;65:879-883
Web of Science | Medline15
Hermsen CC ,Telgt DS ,Linders EH , et al. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol 2001;118:247-251
CrossRef | Web of Science | Medline16
Schneider P ,Wolters L ,Schoone G , et al. Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparum. J Clin Microbiol 2005;43:402-405
CrossRef | Web of Science | Medline17
Houze P ,de Reynies A ,Baud FJ ,Benatar MF ,Pays M . Simultaneous determination of chloroquine and its three metabolites in human plasma, whole blood and urine by ion-pair high-performance liquid chromatography. J Chromatogr 1992;574:305-312
CrossRef | Web of Science | Medline18
Lejeune D ,Souletie I ,Houze S , et al. Simultaneous determination of monodesethylchloroquine, chloroquine, cycloguanil and proguanil on dried blood spots by reverse-phase liquid chromatography. J Pharm Biomed Anal 2007;43:1106-1115
CrossRef | Web of Science | Medline19
Bousema JT ,Roeffen W ,van der Kolk M , et al. Rapid onset of transmission-reducing antibodies in Javanese migrants exposed to malaria in Papua, Indonesia. Am J Trop Med Hyg 2006;74:425-431
Web of Science | Medline20
Hermsen CC ,Verhage DF ,Telgt DS , et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007;25:2930-2940
CrossRef | Web of Science | Medline21
Remarque EJ ,Faber BW ,Kocken CH ,Thomas AW . A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 2008;76:2660-2670
CrossRef | Web of Science | Medline22
McCall MB ,Netea MG ,Hermsen CC , et al. Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J Immunol 2007;179:162-171
Web of Science | Medline23
Verhage DF ,Telgt DS ,Bousema JT , et al. Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med 2005;63:52-58
Web of Science | Medline24
Hermsen CC ,de Vlas SJ ,van Gemert GJ ,Telgt DS ,Verhage DF ,Sauerwein RW . Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg 2004;71:196-201
Web of Science | Medline25
Pombo DJ ,Lawrence G ,Hirunpetcharat C , et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002;360:610-617
CrossRef | Web of Science | Medline26
Edstein MD ,Kotecka BM ,Anderson KL , et al. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob Agents Chemother 2005;49:4421-4422
CrossRef | Web of Science | Medline27
Orjih AU . Acute malaria prolongs susceptibility of mice to Plasmodium berghei sporozoite infection. Clin Exp Immunol 1985;61:67-71
Web of Science | Medline28
Bejon P ,Mwacharo J ,Kai O , et al. The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol 2007;179:4193-4201
Web of Science | Medline29
Grobusch MP ,Egan A ,Gosling RD ,Newman RD . Intermittent preventive therapy for malaria: progress and future directions. Curr Opin Infect Dis 2007;20:613-620
CrossRef | Web of Science | Medline30
Sutherland CJ ,Drakeley CJ ,Schellenberg D . How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malar J 2007;6:161-161
CrossRef | Web of Science | Medline31
Davis JR ,Cortese JF ,Herrington DA , et al. Plasmodium falciparum: in vitro characterization and human infectivity of a cloned line. Exp Parasitol 1992;74:159-168
CrossRef | Web of Science | Medline32
Bejon P ,Keating S ,Mwacharo J , et al. Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naive and malaria-exposed individuals. Infect Immun 2006;74:6331-6338
CrossRef | Web of Science | Medline33
Darrah PA ,Patel DT ,De Luca PM , et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-850
CrossRef | Web of Science | Medline34
Precopio ML ,Betts MR ,Parrino J , et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007;204:1405-1416
CrossRef | Web of Science | Medline35
Hogh B ,Thompson R ,Zakiuddin IS ,Boudin C ,Borre M . Glutamate rich Plasmodium falciparum antigen (GLURP). Parassitologia 1993;35:Suppl:47-50
Medline36
Silvie O ,Franetich JF ,Charrin S , et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 2004;279:9490-9496
CrossRef | Web of Science | Medline37
Krzych U ,Lyon JA ,Jareed T , et al. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. J Immunol 1995;155:4072-4077
Web of Science | Medline
- Citing Articles (57)
Citing Articles
1
D. Lys Guilbride, Patrick D.L. Guilbride, Pawel Gawlinski. (2012) Malaria's deadly secret: a skin stage. Trends in Parasitology
CrossRef2
Claudia A Daubenberger. (2012) First clinical trial of purified, irradiated malaria sporozoites in humans. Expert Review of Vaccines 11:1, 31-33
CrossRef3
Susanne H Sheehy, Christopher JA Duncan, Sean C Elias, Katharine A Collins, Katie J Ewer, Alexandra J Spencer, Andrew R Williams, Fenella D Halstead, Samuel E Moretz, Kazutoyo Miura, Christian Epp, Matthew DJ Dicks, Ian D Poulton, Alison M Lawrie, Eleanor Berrie, Sarah Moyle, Carole A Long, Stefano Colloca, Riccardo Cortese, Sarah C Gilbert, Alfredo Nicosia, Adrian VS Hill, Simon J Draper. (2011) Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Molecular Therapy 19:12, 2269-2276
CrossRef4
Mark J Geels, Egeruan B Imoukhuede, Nathalie Imbault, Harry van Schooten, Terry McWade, Marita Troye-Blomberg, Roland Dobbelaer, Alister G Craig, Odile Leroy. (2011) European Vaccine Initiative: lessons from developing malaria vaccines. Expert Review of Vaccines 10:12, 1697-1708
CrossRef5
Monica L. Mazuz, Richard Haynes, Varda Shkap, Leah Fish, Ricardo Wollkomirsky, Benjamin Leibovich, Thea Molad, Igor Savitsky, Jacob Golenser. (2011) Neospora caninum: in vivo and in vitro treatment with artemisone. Veterinary Parasitology
CrossRef6
Sílvia Portugal, Hal Drakesmith, Maria M Mota. (2011) Superinfection in malaria: Plasmodium shows its iron will. EMBO reports 12:12, 1233-1242
CrossRef7
J. E. Epstein, K. Tewari, K. E. Lyke, B. K. L. Sim, P. F. Billingsley, M. B. Laurens, A. Gunasekera, S. Chakravarty, E. R. James, M. Sedegah, A. Richman, S. Velmurugan, S. Reyes, M. Li, K. Tucker, A. Ahumada, A. J. Ruben, T. Li, R. Stafford, A. G. Eappen, C. Tamminga, J. W. Bennett, C. F. Ockenhouse, J. R. Murphy, J. Komisar, N. Thomas, M. Loyevsky, A. Birkett, C. V. Plowe, C. Loucq, R. Edelman, T. L. Richie, R. A. Seder, S. L. Hoffman. (2011) Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity. Science 334:6055, 475-480
CrossRef8
S. H. I. Kappe, S. A. Mikolajczak. (2011) Another Shot at a Malaria Vaccine. Science 334:6055, 460-461
CrossRef9
A. V. S. Hill. (2011) Vaccines against malaria. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2806-2814
CrossRef10
Wildaliz Nieves, Saja Asakrah, Omar Qazi, Katherine A. Brown, Jonathan Kurtz, David P. AuCoin, James B. McLachlan, Chad J. Roy, Lisa A. Morici. (2011) A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 29:46, 8381-8389
CrossRef11
Geoffrey Ian McFadden. (2011) The apicoplast. Protoplasma 248:4, 641-650
CrossRef12
Charles Arama, Shahid Waseem, Carmen Fernández, Yohannes Assefaw-Redda, Liya You, Ariane Rodriguez, Katarina Radošević, Jaap Goudsmit, Stefan H.E. Kaufmann, Stephen T. Reece, Marita Troye-Blomberg. (2011) A recombinant Bacille Calmette–Guérin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice. Vaccine
CrossRef13
Yanhui Zhang, Yanwei Qi, Jian Li, Shengfa Liu, Lingxian Hong, Tianlong Lin, Carole Long, Xin-zhuan Su. (2011) A new malaria antigen produces partial protection against Plasmodium yoelii challenge. Parasitology Research
CrossRef14
Steffen Borrmann, Kai Matuschewski. (2011) Targeting Plasmodium liver stages: better late than never. Trends in Molecular Medicine 17:9, 527-536
CrossRef15
Johannes Friesen, Kai Matuschewski. (2011) Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine 29:40, 7002-7008
CrossRef16
Joana M. Haussig, Kai Matuschewski, Taco W. A. Kooij. (2011) Inactivation of a Plasmodium apicoplast protein attenuates formation of liver merozoites. Molecular Microbiology 81:6, 1511-1525
CrossRef17
Steffen Borrmann, Kai Matuschewski. (2011) Protective immunity against malaria by ‘natural immunization’: a question of dose, parasite diversity, or both?. Current Opinion in Immunology 23:4, 500-508
CrossRef18
Michael F. Good. (2011) A whole parasite vaccine to control the blood stages of Plasmodium – the case for lateral thinking. Trends in Parasitology 27:8, 335-340
CrossRef19
Roberta Spaccapelo, Elena Aime, Sara Caterbi, Paola Arcidiacono, Barbara Capuccini, Manlio Di Cristina, Tania Dottorini, Mario Rende, Francesco Bistoni, Andrea Crisanti. (2011) Disruption of plasmepsin-4 and merozoites surface protein-7 genes in Plasmodium berghei induces combined virulence-attenuated phenotype. Scientific Reports 1,
CrossRef20
Rosenthal, Philip J., . (2011) Lessons from Sickle Cell Disease in the Treatment and Control of Malaria. New England Journal of Medicine 364:26, 2549-2551
Full Text21
Bruno Douradinha, Denise L. Doolan. (2011) Harnessing immune responses against Plasmodium for rational vaccine design. Trends in Parasitology 27:6, 274-283
CrossRef22
H. Chang, A. Astolfi, H. Shim. (2011) A control theoretic approach to malaria immunotherapy with state jumps. Automatica 47:6, 1271-1277
CrossRef23
Meta Roestenberg, Anne C Teirlinck, Matthew BB McCall, Karina Teelen, Krystelle Nganou Makamdop, Jorien Wiersma, Theo Arens, Pieter Beckers, GeertJan van Gemert, Marga van de Vegte-Bolmer, André JAM van der Ven, Adrian JF Luty, Cornelus C Hermsen, Robert W Sauerwein. (2011) Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. The Lancet 377:9779, 1770-1776
CrossRef24
Brian Greenwood, Geoffrey Targett. (2011) The mysteries of immunity to malaria. The Lancet 377:9779, 1729-1730
CrossRef25
Michael F. Good. (2011) Our impasse in developing a malaria vaccine. Cellular and Molecular Life Sciences 68:7, 1105-1113
CrossRef26
Susana Lousada-Dietrich, Prajakta S. Jogdand, Søren Jepsen, Vera V. Pinto, Sisse B. Ditlev, Michael Christiansen, Severin Olesen Larsen, Christopher B. Fox, Vanitha S. Raman, Randall F. Howard, Thomas S. Vedvick, Gregory Ireton, Darrick Carter, Steven G. Reed, Michael Theisen. (2011) A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 – A GLURP–MSP3 fusion protein malaria vaccine candidate. Vaccine 29:17, 3284-3292
CrossRef27
Alessandra Mortellaro, Paola Ricciardi-Castagnoli. (2011) From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease. Immunology and Cell Biology 89:3, 332-339
CrossRef28
Julius Clemence Hafalla, Olivier Silvie, Kai Matuschewski. (2011) Cell biology and immunology of malaria. Immunological Reviews 240:1, 297-316
CrossRef29
Theo P. M. Schetters. 2011. Alternatives to Drug Development in the Apicomplexa. , 53-73.
CrossRef30
M. INOUE, R. L. CULLETON. (2011) The intradermal route for inoculation of sporozoites of rodent malaria parasites for immunological studies. Parasite Immunology 33:2, 137-142
CrossRef31
R. L. CULLETON, M. INOUE, S. E. REECE, S. CHEESMAN, R. CARTER. (2011) Strain-specific immunity induced by immunization with pre-erythrocytic stages of Plasmodium chabaudi. Parasite Immunology 33:1, 73-78
CrossRef32
Carlos Moneriz, Patricia Marín-García, José M Bautista, Amalia Diez, Antonio Puyet. (2011) Parasitostatic effect of maslinic acid. II. Survival increase and immune protection in lethal Plasmodium yoelii-infected mice. Malaria Journal 10:1, 103
CrossRef33
Michael F Good, Christian Engwerda. (2011) Defying malaria: Arming T cells to halt malaria. Nature Medicine 17:1, 49-51
CrossRef34
Blanca-Liliana Perlaza, Jean-Pierre Sauzet, Karima Brahimi, Lbachir BenMohamed, Pierre Druilhe. (2011) Interferon-γ, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity. Malaria Journal 10:1, 27
CrossRef35
Robert W. Sauerwein, Meta Roestenberg, Vasee S. Moorthy. (2011) Experimental human challenge infections can accelerate clinical malaria vaccine development. Nature Reviews Immunology 11:1, 57-64
CrossRef36
Peter D. Crompton, Susan K. Pierce, Louis H. Miller. (2010) Advances and challenges in malaria vaccine development. Journal of Clinical Investigation 120:12, 4168-4178
CrossRef37
Quirijn De Mast, Philip G. De Groot, Waander L. Van Heerde, Meta Roestenberg, Jeroen F. Van Velzen, Bert Verbruggen, Mark Roest, Matthew McCall, An-Emmie Nieman, Josien Westendorp, Din Syafruddin, Rob Fijnheer, Edmee C. Van Dongen-Lases, Robert W. Sauerwein, Andre J. Van Der Ven. (2010) Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. British Journal of Haematology 151:5, 495-503
CrossRef38
Alexander D. Douglas, Simone C. de Cassan, Matthew D.J. Dicks, Sarah C. Gilbert, Adrian V.S. Hill, Simon J. Draper. (2010) Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28:44, 7167-7178
CrossRef39
Alberto Pinzon-Charry, Virginia McPhun, Vivian Kienzle, Chakrit Hirunpetcharat, Christian Engwerda, James McCarthy, Michael F. Good. (2010) Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. Journal of Clinical Investigation 120:8, 2967-2978
CrossRef40
J. Friesen, O. Silvie, E. D. Putrianti, J. C. R. Hafalla, K. Matuschewski, S. Borrmann. (2010) Natural Immunization Against Malaria: Causal Prophylaxis with Antibiotics. Science Translational Medicine 2:40, 40ra49-40ra49
CrossRef41
P. A. Darrah, S. T. Hegde, D. T. Patel, R. W. B. Lindsay, L. Chen, M. Roederer, R. A. Seder. (2010) IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. Journal of Experimental Medicine 207:7, 1421-1433
CrossRef42
Brandy Lee Bennett, Photini Sinnis. (2010) What can we learn from an unnatural immune response?. Trends in Parasitology 26:7, 319-321
CrossRef43
Cevayir Coban, Toshihiro Horii, Shizuo Akira, Ken J Ishii. (2010) TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine. Expert Review of Vaccines 9:7, 775-784
CrossRef44
Takafumi Tsuboi, Satoru Takeo, Thangavelu U. Arumugam, Hitoshi Otsuki, Motomi Torii. (2010) The wheat germ cell-free protein synthesis system: A key tool for novel malaria vaccine candidate discovery. Acta Tropica 114:3, 171-176
CrossRef45
Robert W Sauerwein, Else M Bijker, Thomas L Richie. (2010) Empowering malaria vaccination by drug administration. Current Opinion in Immunology 22:3, 367-373
CrossRef46
Cristina T. Stoyanov, Silvia B. Boscardin, Stephanie Deroubaix, Giovanna Barba-Spaeth, David Franco, Ruth S. Nussenzweig, Michel Nussenzweig, Charles M. Rice. (2010) Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine 28:29, 4644-4652
CrossRef47
Stephen M. Todryk. (2010) A natural immunization process prevents malaria. Trends in Parasitology 26:5, 219-221
CrossRef48
A. L. Goodman, S. J. Draper. (2010) Blood-stage malaria vaccines — recent progress and future challenges. Annals of Tropical Medicine and Parasitology 104:3, 189-211
CrossRef49
Vasee S Moorthy, Marie Paule Kieny. (2010) Reducing empiricism in malaria vaccine design. The Lancet Infectious Diseases 10:3, 204-211
CrossRef50
Benjamin Mordmüller. (2010) New medicines for malaria. Wiener klinische Wochenschrift 122:S1, 19-22
CrossRef51
Satarudra P. Singh, Feroz Khan, Bhartendu N. Mishra. (2010) Computational characterization of Plasmodium falciparum proteomic data for screening of potential vaccine candidates. Human Immunology 71:2, 136-143
CrossRef52
R. Fears, J. W. M. van der Meer, V. ter Meulen. (2010) Translational Medicine Policy Issues in Infectious Disease. Science Translational Medicine 2:14, 14cm2-14cm2
CrossRef53
Ruobing Wang, Joseph D. Smith, Stefan H.I. Kappe. (2009) Advances and challenges in malaria vaccine development. Expert Reviews in Molecular Medicine 11,
CrossRef54
Claudio Silveira, Nicola Gargano, Aize Kijlstra, Eskild Petersen. (2009) Toxoplasma vaccines: appropriate end points and sample size in future human clinical trials. Expert Review of Anti-infective Therapy 7:8, 905-908
CrossRef55
(2009) News in brief. Nature Medicine 15:9, 980-981
CrossRef56
A. Varki, P. Gagneux. (2009) Human-specific evolution of sialic acid targets: Explaining the malignant malaria mystery?. Proceedings of the National Academy of Sciences 106:35, 14739-14740
CrossRef57
Campbell, Carlos C., . (2009) Malaria Control — Addressing Challenges to Ambitious Goals. New England Journal of Medicine 361:5, 522-523
Full Text
